Production of interleukin-1β and tumour necrosis factor-α in patients with benign or malignant ovarian tumours

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF01613293PMCID PMC12201245
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease

  2004cited by this paper
• [Phase I study].

  1995cited by this paper
• Tumor necrosis factor.

  1991cited by this paper
• In situ detection of tumour necrosis factor in human ovarian cancer specimens.

  1990cited by this paper
• Tumor necrosis factor in children with malignancies.

  1990cited by this paper
• Interleukin 1: the first interleukin.

  1990cited by this paper
• Cells secreting tumour necrosis factor show enhanced metastasis in nude mice.

  1990cited by this paper
• Intrasplenic immunization with minute amounts of antigen.

  1990cited by this paper
• Detection of tumour necrosis factor/cachectin in pleural effusion of patients with lung cancer

  1990cited by this paper
• Interleukin-1α and tumor necrosis factor-α protect cells against natural killer cell-mediated cytotoxicity and natural killer cytotoxic factor

  1990cited by this paper
• Serum levels of tumor necrosis factor-alpha in hairy cell leukemia.

  1990cited by this paper
• High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia.

  1989cited by this paper
• High-Level Secretion of Tumor Necrosis Factor-alpha Contributes to Hematopoietic Failure in Hairy Cell Leukemia

  1989cited by this paper
• Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.

  1989cited by this paper
• Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.

  1989cited by this paper
• Interleukin‐1β induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti‐tumor effects of tumor necrosis factor α or β

  1989cited by this paper
• Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization.

  1989cited by this paper
• Regulation of lymphocyte tumor necrosis factor receptors by IL-2.

  1989cited by this paper
• Immunotherapy of cancer using interleukin 2: current status and future prospects.

  1988cited by this paper
• Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells.

  1988cited by this paper
• Human interferon as a therapeutic agent: a decade passes.

  1988cited by this paper
• Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.

  1988cited by this paper
• The biology of interleukin 1 and comparison to tumor necrosis factor.

  1987cited by this paper
• Evidence for tumour necrosis factor/cachectin production in cancer.

  1987cited by this paper
• Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate.

  1987cited by this paper
• Reduced production of tumor necrosis factor by mononuclear cells in hairy cell leukemia patients and improvement following interferon therapy

  1987cited by this paper
• Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma.

  1987cited by this paper
• Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.

  1987cited by this paper
• Modulation of the Growth of Transformed Cells by Human Tumor Necrosis Factor-α and Interferon-γ

  1987cited by this paper
• Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.

  1987cited by this paper
• Secretory products of macrophages.

  1987cited by this paper
• Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

  1987cited by this paper
• Raised serum levels of tumour necrosis factor in parasitic infections.

  1986cited by this paper
• There is more than one interleukin 1.

  1986cited by this paper
• Detection of Tumour Necrosis Factor‐Like Cytotoxicity in Serum from Patients With Septicaemia but Not from Untreated Cancer Patients

  1986influential reference
• Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1

  1986cited by this paper
• Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity.

  1985cited by this paper
• Human interleukin 1 is a cytocidal factor for several tumor cell lines.

  1985cited by this paper
• Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

  1985cited by this paper
• Cachectin/tumour-necrosis-factor production by cancer patients.

  1985cited by this paper
• Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice

  1984influential reference
• Two distinct factors are required for induction of T-cell growth

  1980cited by this paper
• Human interferon as a therapeutic agent.

  1979cited by this paper
• An endotoxin-induced serum factor that causes necrosis of tumors.

  1975cited by this paper

• Clinical relevance of the number of interleukin-17-producing CD 8+ T cells in patients with gastric cancer

  2015cites this paper
• Weight control and cancer preventive mechanisms: Role of insulin growth factor-1-mediated signaling pathways

  2013cites this paper
• Apolipoprotein Concentrations Are Elevated in Malignant Ovarian Cyst Fluids Suggesting That Lipoprotein Metabolism Is Dysregulated in Epithelial Ovarian Cancer

  2013cites this paper
• Ovarian Cyst Fluids Are a Cache of Tumor Biomarkers That Include Calgranulin A and Calgranulin B Isoforms

  2013cites this paper
• Suplementação de óleo de peixe em câncer colorretal: efeitos sobre a resposta inflamatória, o estado nutricional, o perfil de ácidos graxos plasmáticos e a tolerância à quimioterapia

  2012cites this paper
• Inflammation and cancer: how friendly is the relationship for cancer patients?

  2009cites this paper
• Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.

  2008cites this paper
• Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas

  2005cites this paper
• Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.

  2003cites this paper